Inovio Inks $44M Cash, Stock Deal To End COVID-19 Vax Suit

By Emilie Ruscoe · August 23, 2022, 8:55 PM EDT

Biotechnology firm Inovio Pharmaceuticals Inc. has reached a $44 million settlement agreement with its investors, which if approved would end claims that the company's misrepresentation of its COVID-19 vaccine development efforts...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

MCDERMID v. INOVIO PHARMACEUTICALS, INC. et al

Case Number

2:20-cv-01402

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Date Filed

March 12, 2020